Can I Take N-Acetylcysteine (NAC) with Praluent (Alirocumab)?

How Alirocumab Works and Why the Interaction Question Arises

Alirocumab is a fully human monoclonal IgG1 antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing PCSK9 from degrading LDL receptors on hepatocytes. More LDL receptors on liver cells means more circulating LDL-C is cleared from the bloodstream. The FDA approved alirocumab in August 2015, and in ODYSSEY OUTCOMES (N=18,924), the drug reduced major adverse cardiovascular events by 15% relative to placebo over a median 2.8-year follow-up (1).

NAC enters the picture because it is one of the most widely used supplements for cardiovascular, respiratory, and metabolic health. Patients prescribed alirocumab for familial hypercholesterolemia (FH) or established atherosclerotic cardiovascular disease (ASCVD) frequently ask whether the antioxidant effects of NAC could interfere with, or add to, what their PCSK9 inhibitor is already doing.

The Biological Distance Between the Two Agents

Alirocumab is a large-protein biologic. It is not absorbed orally, not metabolized by hepatic cytochrome P450 enzymes, and not excreted via renal tubular transporters. Its pharmacokinetic profile follows IgG antibody catabolism: proteolytic degradation into peptides and amino acids in reticuloendothelial tissues (2).

NAC, by contrast, is a small-molecule thiol. After oral ingestion, it is deacetylated in intestinal and hepatic tissue to free cysteine, which is then used for glutathione synthesis. Peak plasma concentration of NAC occurs within 1 to 2 hours of ingestion. Hepatic CYP450 enzymes play a negligible role in its metabolism (3).

Because the two substances occupy entirely separate metabolic compartments, no pharmacokinetic interaction pathway exists. One is a protein, the other is a thiol amino-acid derivative. They do not compete for the same transporters, enzymes, or plasma-protein binding sites.

Why Pharmacodynamic Overlap Still Warrants Attention

Even without a pharmacokinetic interaction, two agents can produce additive or opposing physiological effects. With alirocumab and NAC, the relevant overlap is lipid-related oxidative stress.

LDL oxidation is a key early step in atherosclerotic plaque formation. NAC raises intracellular glutathione concentrations, which may reduce the oxidation of LDL particles (4). Alirocumab lowers LDL-C concentration itself, reducing the total substrate available for oxidation. These actions are complementary rather than antagonistic. No published study has shown that NAC blunts the LDL-C-lowering effect of alirocumab or any other PCSK9 inhibitor.

What the Evidence Says About NAC and Lipid Metabolism

NAC has been studied independently for its effects on lipid panels, particularly in populations with elevated oxidative stress such as PCOS, type 2 diabetes, and non-alcoholic fatty liver disease. Understanding what NAC does to lipids on its own helps clinicians predict whether concurrent use with alirocumab creates any practical concern.

NAC and LDL-C: Direct Evidence

A 2015 randomized controlled trial in women with PCOS (N=60) found that NAC 1,800 mg/day for 24 weeks produced a statistically significant reduction in total cholesterol (mean reduction 14.3 mg/dL, P<0.01) compared with placebo (5). LDL-C fell modestly but did not reach statistical significance as a primary endpoint.

A 2019 meta-analysis of NAC supplementation (7 RCTs, N=429) reported a weighted mean reduction in total cholesterol of 9.6 mg/dL and in triglycerides of 15.2 mg/dL, with no consistent effect on HDL-C (6). The magnitude is small relative to alirocumab's typical LDL-C reduction of 43 to 57% in ODYSSEY LONG TERM (N=2,341) (7).

The practical takeaway: NAC may lower LDL-C by a few milligrams per deciliter through antioxidant pathways. Alirocumab lowers LDL-C by 43 to 57% through receptor upregulation. The combination does not appear to produce any clinically problematic additive hypocholesterolemia. Excessively low LDL-C (below 20 to 25 mg/dL) is theoretically a concern with very high-dose PCSK9 inhibitor therapy, but NAC's contribution to LDL reduction is too small to create that scenario.

NAC and Homocysteine

One biochemical signal worth tracking: NAC increases the availability of cysteine, one of the three amino acids required to synthesize glutathione. Indirectly, this can modestly lower homocysteine concentrations by diverting the homocysteine-to-cysteine transsulfuration pathway (8). Elevated homocysteine is an independent cardiovascular risk marker. Lowering it theoretically aligns with the same cardiovascular-protection goals as alirocumab therapy.

This is not a drug interaction. It is a potentially favorable physiological direction for patients already on PCSK9 inhibitor therapy for ASCVD risk reduction.

NAC and Platelet Function

At doses above 3,000 mg/day, NAC has demonstrated antiplatelet effects in vitro and in small clinical studies (9). Alirocumab has no known antiplatelet pharmacology. Patients on concurrent anticoagulants or antiplatelets (aspirin, clopidogrel) should inform their prescriber if they are taking high-dose NAC, since the antiplatelet signal adds to existing bleeding risk considerations. This is not a reason to avoid NAC with alirocumab specifically, but the full medication and supplement list should be reviewed together.

Alirocumab's Known Drug Interaction Profile

Alirocumab's interaction risk is lower than most small-molecule drugs. Because it bypasses hepatic CYP450 metabolism entirely, it does not interact with statins, fibrates, or most other cardiovascular drugs at the pharmacokinetic level. The FDA-approved prescribing information for Praluent does not list any supplement as a contraindicated co-administration (10).

Documented Pharmacokinetic Safety

A population pharmacokinetic analysis published alongside the ODYSSEY program found alirocumab clearance was not meaningfully altered by concurrent statin use, ezetimibe, fibrates, or niacin (11). NAC would have an even lower probability of interacting given its distinct metabolic fate.

Injection-Site Considerations

Alirocumab is injected subcutaneously. NAC has no local tissue interaction with subcutaneous injection sites. No topical or systemic interference with monoclonal antibody absorption from the subcutaneous depot has been attributed to NAC in any published case report or pharmacovigilance database entry.

Immunogenicity

Monoclonal antibodies can theoretically trigger anti-drug antibody formation, which would reduce efficacy. Antioxidants like NAC do not amplify immune responses in a way that would accelerate anti-PCSK9-antibody production. The anti-alirocumab antibody rate in ODYSSEY LONG TERM was 4.8% overall and was not linked to any supplement co-administration (7).

Special Populations Using Both NAC and Alirocumab

Women with PCOS and Cardiovascular Risk

NAC has an established off-label use in polycystic ovary syndrome (PCOS). A 2015 Cochrane review assessed NAC in PCOS and found improvements in ovulation and metabolic markers (12). Women with PCOS carry a higher-than-average lifetime risk of ASCVD, and some may also qualify for alirocumab under familial hypercholesterolemia criteria or very high ASCVD-risk thresholds.

For these patients, concurrent NAC and alirocumab therapy is not contraindicated. The relevant monitoring points are:

• Fasting lipid panel at 4 to 8 weeks after alirocumab initiation to confirm target LDL-C is reached.
• Liver enzymes if NAC is dosed at or above 1,800 mg/day for extended periods, since acetaminophen and certain hepatotoxic drugs can interact with NAC's thiol chemistry. Alirocumab itself is not hepatotoxic.
• Menstrual cycle and androgen markers if NAC is being used for PCOS ovulation induction alongside statin or PCSK9 therapy.

Patients with Chronic Respiratory Conditions

NAC is approved as a mucolytic at doses of 600 to 1,200 mg/day in several European countries, and used off-label at similar doses in the United States for chronic obstructive pulmonary disease (COPD) and bronchiectasis. COPD patients carry high ASCVD risk and may appropriately receive alirocumab. No respiratory pharmacology of alirocumab would interact with the mucolytic mechanism of NAC.

Patients with Acetaminophen Toxicity

High-dose intravenous NAC (150 mg/kg loading dose) is the standard antidote for acetaminophen overdose. Patients receiving IV NAC acutely are rarely also on scheduled subcutaneous alirocumab, but if they are, no pharmacological conflict exists. The hepatoprotective mechanism of IV NAC does not alter PCSK9 receptor biology.

Monitoring Parameters When Taking Both

Even without a direct drug-supplement interaction, patients taking alirocumab and NAC together benefit from systematic monitoring. A structured approach minimizes the small probability of an undetected physiological signal.

Lipid Panel Schedule

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol recommends checking a fasting lipid panel 4 to 12 weeks after initiating or adjusting PCSK9 inhibitor therapy and every 3 to 12 months thereafter (13). If NAC is added to a stable alirocumab regimen, repeating the lipid panel at 6 to 8 weeks gives clinicians a clean read on whether the combination has shifted LDL-C in a clinically meaningful direction.

Liver Function

Alirocumab does not require routine liver function monitoring per its FDA label. NAC at doses above 1,800 mg/day taken long-term has not been shown to cause hepatotoxicity in healthy adults, but baseline ALT and AST are reasonable to obtain before starting high-dose NAC in any patient with metabolic liver disease (14).

Renal Function

Neither alirocumab nor NAC requires dose adjustment for mild-to-moderate renal impairment. Severe renal impairment (eGFR <15 mL/min/1.73 m²) warrants specialist involvement for both agents, though the concern with NAC in that setting is accumulation of its sulfur metabolites rather than any alirocumab-related mechanism.

Practical Dosing Guidance for Patients Already Taking Both

Patients who are already taking NAC and receive a new alirocumab prescription (or vice versa) do not need to change their current supplement timing or dose to accommodate the biologic injection schedule.

Alirocumab is injected once every 2 weeks (75 mg or 150 mg) or once every 4 weeks (300 mg) at any time of day, independent of meals. NAC is typically taken with meals to reduce gastrointestinal side effects (nausea is the most common adverse effect, reported in approximately 7 to 11% of oral NAC users). No pharmacological reason exists to separate the alirocumab injection day from NAC dosing. No "washout" period is needed before starting either agent if the other is already in use.

The standard starting dose for alirocumab in ASCVD patients is 75 mg every 2 weeks, with titration to 150 mg every 2 weeks if LDL-C remains above the guideline target of <70 mg/dL after 4 to 8 weeks (13). NAC doses used in cardiovascular and metabolic studies range from 600 mg to 1,800 mg/day. Neither the alirocumab dose selection nor its titration schedule needs to account for concurrent NAC use.

What Clinicians Say About PCSK9 Inhibitors and Antioxidant Supplements

The American College of Cardiology's 2022 Expert Consensus Decision Pathway on Novel Therapies for LDL Lowering states: "Supplements and nutraceuticals with modest LDL-lowering effects may be used in patients who are intolerant of or decline statin therapy, but they should not be substituted for evidence-based pharmacotherapy in high-risk patients" (15).

This framing positions NAC (if used for lipid modulation) as a complementary tool, not a replacement for alirocumab. For patients who are already on alirocumab for FH or ASCVD, adding NAC for antioxidant, respiratory, or PCOS indications does not conflict with that evidence-based treatment hierarchy.

Dr. Scott Grundy, lead author of the 2018 ACC/AHA cholesterol guidelines, has written that "non-statin agents that reduce LDL-C are additive to statins" and by extension to PCSK9 inhibitors, provided their safety profiles are acceptable (13). NAC's modest lipid effects and favorable safety profile fit that framework.

When to Contact Your Prescriber

Most patients can continue NAC while starting alirocumab without any special precautions beyond routine lipid monitoring. Contact your prescriber before combining the two agents if:

• Your NAC dose exceeds 3,000 mg/day (antiplatelet signal becomes more relevant).
• You are taking concurrent anticoagulants such as warfarin, rivaroxaban, or apixaban.
• You have moderate-to-severe liver disease (Child-Pugh B or C), where both NAC metabolism and PCSK9 receptor biology are altered.
• Your LDL-C at 8 weeks post-alirocumab is unexpectedly below 30 mg/dL, which warrants a full medication and supplement review.
• You experience new symptoms such as bruising, unusual fatigue, or gastrointestinal bleeding after starting either agent.